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Summary
Background Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: 64 Gy in 
32 fractions over 6·5 weeks and a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks. Long-term 
outcomes of these schedules in several cohort studies and case series suggest that response, survival, and toxicity are 
similar, but no direct comparison has been published. The present study aimed to assess the non-inferiority of 55 Gy 
in 20 fractions to 64 Gy in 32 fractions in terms of invasive locoregional control and late toxicity in patients with 
locally advanced bladder cancer.
Methods We did a meta-analysis of individual patient data from patients (age ≥18 years) with locally advanced bladder 
cancer (T1G3 [high-grade non-muscle invasive] or T2–T4, N0M0) enrolled in two multicentre, randomised, controlled, 
phase 3 trials done in the UK: BC2001 (NCT00024349; assessing addition of chemotherapy to radiotherapy) and 
BCON (NCT00033436; assessing hypoxia-modifying therapy combined with radiotherapy). In each trial, the 
fractionation schedule was chosen according to local standard practice. Co-primary endpoints were invasive 
locoregional control (non-inferiority margin hazard ratio [HR]=1·25); and late bladder or rectum toxicity, assessed 
with the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic tool (non-inferiority 
margin for absolute risk difference [RD]=10%). If non-inferiority was met for invasive locoregional control, superiority 
could be considered if the 95% CI for the treatment effect excluded the null effect (HR=1). One-stage individual 
patient data meta-analysis models for the time-to-event and binary outcomes were used, accounting for trial 
differences, within-centre correlation, randomised treatment received, baseline variable imbalances, and potential 
confounding from relevant prognostic factors.
Findings 782 patients with known fractionation schedules (456 from the BC2001 trial and 326 from the BCON trial; 
376 (48%) received 64 Gy in 32 fractions and 406 (52%) received 55 Gy in 20 fractions) were included in our meta-
analysis. Median follow-up was 120 months (IQR 99–159). Patients who received 55 Gy in 20 fractions had a lower risk 
of invasive locoregional recurrence than those who received 64 Gy in 32 fractions (adjusted HR 0·71 [95% CI 
0·52–0·96]). Both schedules had similar toxicity profiles (adjusted RD –3·37% [95% CI –11·85 to 5·10]).
Interpretation A hypofractionated schedule of 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fractions with regard 
to both invasive locoregional control and toxicity, and is superior with regard to invasive locoregional control. 55 Gy in 
20 fractions should be adopted as a standard of care for bladder preservation in patients with locally advanced bladder 
cancer.
Funding Cancer Research UK.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Bladder preservation therapy is an alternative to surgery 
for the management of locally advanced bladder cancer. 
Typically, this strategy comprises pretreatment staging 
with transurethral resection of the tumour and cross-
sectional imaging, followed by radiotherapy with or 
without a radiosensitiser. Radiotherapy might also be 
preceded by neoadjuvant chemotherapy. Combining 
radiotherapy with a radiosensitiser gives similar rates of 
disease-specific survival and overall survival (about 50% at 
5 years for both endpoints) compared with surgery.1–4 
The two largest phase 3, randomised, controlled trials 
of bladder preservation showed benefit in terms of 
locoregional disease-free survival (the BC2001 trial3,5) and 
overall survival (BCON1) with use of chemotherapy 
(BC2001) or hypoxia-modifying therapy (BCON) concur-
rent with radiotherapy, compared with radiotherapy alone.
Both trials permitted two commonly used radiotherapy 
fractionation schedules, 64 Gy in 32 fractions over 
6·5 weeks and a hypofractionated schedule of 55 Gy in 
20 fractions over 4 weeks. Although no direct com-
parisons of these schedules have been made previously, 
published case series and cohort studies suggest that 
outcomes and late toxicity are similar.6 The present study 
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aimed to assess whether 55 Gy in 20 fractions is non-
inferior to 64 Gy in 32 fractions in terms of invasive 
locoregional control and late bladder and bowel toxicity, 
by assessing combined individual patient data from the 
BC2001 and BCON randomised, phase 3 trials.
Methods
Study design and participants
We did a meta-analysis of individual patient data from 
patients with invasive bladder cancer enrolled in the 
multicentre, randomised, controlled, phase 3 trials 
BC20013,5 and BCON.1 The trials, including full eligibility 
criteria, procedures, and statistical analysis plans, have 
been previously reported. Inclusion and exclusion 
criteria were similar between the trials (appendix p 1). 
Briefly, BC2001 (NCT00024349) was a phase 3, 
randomised trial.3,5 458 patients (age ≥18 years) from 
45 UK National Health Service (NHS) radiotherapy 
departments with a diagnosis of transitional cell bladder 
carcinoma (stage T2–T4N0M0) suitable for treatment 
with radical radiotherapy were recruited. Patients were 
randomly assigned with a partial two-by-two factorial 
design (1:1 in each randomisation) to receive either 
radiotherapy alone or radiotherapy with concomitant 
chemotherapy (fluorouracil [500 mg/m² body surface 
area per day on days 1–5 and days 16–20] and mitomycin C 
[12 mg/m² on day 1]); and either standard whole-bladder 
radiotherapy or reduced high-dose volume radiotherapy 
with tumour boost.
BCON (NCT00033436) was a phase 3, randomised 
trial with parallel design.1 333 patients (age ≥18 years) 
from 13 UK NHS radiotherapy departments (of which 
eight were common to both trials) with a diagnosis of 
transitional cell bladder carcinoma (stages T1G3N0M0 
[high-grade non-muscle invasive] to T4aN0M0) were 
recruited. Patients were randomly assigned (1:1) to 
radiotherapy with or without hypoxia modification with 
carbogen (2% CO2 and 98% O2 at 15 L/min for 5 min 
before and during each fraction) and nicotinamide (orally 
at 40–60 mg/kg, given 1·5–2·0 h before each fraction). 
All patients in the BCON trial received standard whole 
bladder radiotherapy.
In both trials, fractionation schedule for radiotherapy 
(64 Gy in 32 fractions over 6·5 weeks or 55 Gy in 
20 fractions over 4 weeks) was chosen by each 
participating centre according to local standard practice. 
Radiotherapy was delivered with a conventional or 
3D conformal technique when the bladder was empty. 
An expansion of 1·5 cm was used from clinical target 
volume to planned target volume. Pelvic lymph nodes 
were not included in the clinical target volume. Generally, 
all patients at the same site were treated with the same 
fractionation schedule, but with exceptions at six sites 
(four sites in BC2001 and two sites in BCON). Initial 
staging was ascertained in both trials by cystoscopic 
examination and biopsy to confirm histological diagnosis, 
CT or MRI of the abdomen and pelvis, and chest 
radiography (chest CT also allowed in BC2001).
Tumour control was assessed in BC2001 by means of 
physical examination, chest radiography, and rigid or 
flexible cystoscopy at 6, 9, and 12 months after 
randomisation, and then annually. Biopsy of the tumour 
bed and normal bladder was mandated at 6 months and 
repeated as indicated at subsequent cystoscopies. CT of 
Research in context
Evidence before this study
Before this individual patient data meta-analysis was initiated 
(Jan 1, 2019), to our knowledge no published randomised 
controlled trials or meta-analyses comparing the two most 
common radiotherapy dose and fraction schedules used in 
muscle-invasive bladder cancer were available. Both 64 Gy in 
32 fractions and a hypofractionated schedule of 55 Gy in 
20 fractions are used as standard treatment in the UK and were 
part of the protocols in the BC2001 and BCON phase 3, 
randomised, controlled trials. We searched PubMed using the 
terms (hypofractionated radiotherapy AND muscle-invasive 
bladder cancer) AND (loco-regional control) AND (overall 
survival) for clinical trials and meta-analyses published up to 
May 31, 2020, without language restrictions. We identified no 
studies directly comparing the two schedules, although 
published series suggested that outcome and late toxicity were 
similar.
Added value of this study
To our knowledge, this study is the first published individual 
patient data meta-analysis comparing outcomes from the 
two most commonly used radiotherapy schedules for muscle-
invasive bladder cancer. We aimed to confirm that moderately 
hypofractionated radiotherapy with 55 Gy in 20 fractions over 
4 weeks was non-inferior to 64 Gy in 32 fractions over 
6·5 weeks for invasive locoregional control at 5 years. This study 
provides evidence that moderately hypofractionated 
radiotherapy was indeed non-inferior with respect to invasive 
locoregional control and late bladder and rectum toxicity, and 
significantly improved invasive locoregional control. The 
observed benefit was robust regardless of radiosensitisation or 
radiosensitiser.
Implications of all the available evidence
With these findings, 55 Gy in 20 fractions over 4 weeks should be 
considered as the new standard of care for bladder preservation 
therapy in patients with muscle-invasive bladder cancer.
See Online for appendix
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the abdomen and pelvis was done at 1 year and 2 years 
after randomisation and then as indicated. In BCON, 
cystoscopic examination occurred 6 months after 
radiotherapy, and every 6 months for up to 5 years; CT 
and upper tract endoscopy were done when indicated 
from cystoscopy. Management of patients who relapsed 
was according to local site practice in both trials.
In BC2001, annual follow-up for disease events 
(recurrence of local or distant disease) and patient status 
was prospectively collected up to July 11, 2016. In BCON, 
recruiting sites were contacted in 2018 to obtain long-
term survival data (recurrence of local or distant disease 
and patient status), with a data lock on Oct 31, 2018.
Both trials measured late toxicity up to 5 years after the 
end of radiotherapy with the Late Effects Normal Tissue 
Task Force (LENT)-Subjective, Objective, Management, 
Analytic (SOMA)7,8 tool. In BCON, only urinary and rectal 
dysfunction subscales were recorded, and they were 
assessed more frequently (every 3 months in year 1 and 
every 6 months in years 2–5) than in BC2001 (every 
3 months in year 1, and annually thereafter). In the 
BC2001 trial, health-related quality of life (HRQOL) was 
assessed at the end of treatment, 6 months and 12 months 
after randomisation, and then annually up to 5 years with 
the Functional Assessment of Cancer Therapy-Bladder 
(FACT-BL) module.9 A similar HRQOL schedule was 
planned in BCON, but data return was sparse and 
analysis was not pursued.
Details on the key features and endpoints of both trials 
are summarised in the appendix (p 2).
Statistical analysis
Based on information available in both trials, we defined 
common endpoints for the meta-analysis. The co-primary 
endpoints were invasive locoregional control, defined as 
the rate of control of invasive bladder recurrence or 
recurrence in pelvic nodes (ie, invasive locoregional 
recurrence), and late rectum or bladder toxicity.
The timepoint of interest for the invasive locoregional 
control estimate was 3 years. To account for the difference 
in length of disease follow-up assessments between trials, 
the period of observation was set at 5 years. Patients were 
therefore censored at 5 years if known to be alive and 
disease-free; at last known disease assessment if alive and 
disease-free with less than 5 years follow-up; at the date 
of distant recurrence (unless invasive locoregional 
recurrence was diagnosed within 30 days after diagnosis 
of distant recurrence, to account for delay in confirming 
diagnoses); at the date of diagnosis of a second primary 
tumour (only collected in BC2001); or at the date of death 
due to any cause (if recurrence free).
Late toxicity was measured by the proportion of patients 
who had a grade 3–4 rectum or bladder adverse event as 
assessed by the LENT-SOMA scale, during the 5 years 
after randomisation.
The secondary endpoint was overall survival, defined 
as time from the date of randomisation to the date of 
death due to any cause. Patients alive at their last known 
follow-up were censored. All follow-up periods available 
in either trial were used for this endpoint. As a post-hoc 
endpoint of our meta-analysis, we evaluated bladder 
cancer-specific survival, defined as time from random-
isation to death due to bladder cancer; patients who died 
due to other causes were censored at their date of death. 
A further post-hoc exploratory endpoint was change 
from baseline in HRQOL (BC2001 only).
Individual patient data were combined into one dataset. 
All patients in the BCON and BC2001 trials who received 
at least one fraction of radiotherapy and for whom the 
fractionation schedule was known were included in the 
meta-analysis. Given that the fractionation schedules were 
not randomised and confounding was likely to occur, a 
one-stage individual patient data meta-analysis approach 
was chosen due to its flexibility to adjust for potential 
confounders10–12 while preserving clustering within each 
trial.13 As trials differed in baseline data collection, this 
affected the confounders we could adjust for. We explored 
sex, age, allocation to radiosensitiser and reduced high-
dose volume radiotherapy interventions, tumour stage 
and grade, extent of resection, use of neoadjuvant 
chemotherapy, and haemoglobin, which were collected in 
both trials. Imbalance in baseline characteristics was 
investigated with standardised differences,14,15 which 
provided a common scale (%) for the magnitude of 
imbalance between fractionation groups for all baseline 
variables. Any variables with a greater than 10% 
standardised difference in the combined dataset were 
considered potential confounders and investigated in the 
meta-analysis.
We hypothesised that 55 Gy in 20 fractions would be 
non-inferior to 64 Gy in 32 fractions in terms of disease 
control and late toxicity. For each endpoint, non-inferiority 
would be declared if the upper limit of the 95% CI of the 
estimated fractionation differences was smaller than the 
non-inferiority margin. The prespecified non-inferiority 
margin for invasive locoregional control was a hazard 
ratio (HR) of HRnon-inferiority=1·25, and for late bladder and 
rectum toxicity, an absolute risk difference (RD) of 
RDnon-inferiority=10%. Statistical significance was assessed 
with 95% CIs, with 5% significance corresponding to the 
null hypothesis value being outside the 95% CI. If non-
inferiority was met for invasive locoregional control, 
superiority could be considered if the 95% CI for the 
treatment effect excluded the null effect (HR=1).
For the time-to-event endpoints, a crude analysis to 
estimate the hazard ratio (HR) representing the relative 
difference between fraction ation schedules was first 
done by fitting a stratified Cox proportional hazards 
model with fractionation schedule as the predictor, a 
frailty term for site clustering, and stratifying by trial. An 
adjusted HR (aHR) for fractionation effect was fitted 
similarly, but incorporating trial intervention (allocated 
use of concurrent radio sensitiser), prespecified 
prognostic factors, and any potential con founder with 
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baseline imbalance (leading to >10% variation in the 
crude fractionation effect when the potential confounder 
was added to the model) or showing univariable 
association (at the 5% level) with the endpoint. As in the 
BC2001 trial, prespecified prognostic factors for invasive 
locoregional control were age, sex, tumour stage, use of 
neoadjuvant chemotherapy, and extent of resection; and 
for overall survival were age and sex.16 Model assumptions 
were assessed by graphical assessment of residuals. A 
likelihood ratio test for heterogeneity of fractionation 
effect across trials was done by considering an extended 
model including the interaction of fractionation schedule 
and trial.
For the analysis of grade 3–4 rectum and bladder 
toxicities within 5 years, toxicities reported within 
3 months before first recurrence or death related to 
bladder cancer were treated as missing to avoid 
interpreting recurrence symptoms as toxicities. As a 
sensitivity analysis, we present the results when such 
censoring was not done. The absolute RD between 
fractionation schedules in having grade 3–4 rectum or 
bladder toxicity over 5 years was estimated with a 
generalised linear binomial model with a random 
intercept for treatment site, to account for clustering 
within sites.17 A crude model was first fitted for 
fractionation schedule including trial as a fixed effect. In 
the adjusted analysis, we also included trial intervention, 
age, sex, and any potential confounder with baseline 
imbalance (leading to >10% variation in the crude 
fractionation relative effect) or showing univariable 
association (at the 5% level) with the toxicity outcome. 
Each model was adjusted on the subset of patients with 
182 included in meta-analysis
Combined dataset
782 included in meta-analysis
 376 received 64 Gy in 32 fractions
 406 received 55 Gy in 20 fractions
111 received 
 64 Gy in 
 32 fractions
71 received
 55 Gy in
 20 fractions
168 received
 64 Gy in
 32 fractions
106 received
 55 Gy in
 20 fractions
49 received
 64 Gy in
 32 fractions
116 received
 55 Gy in
 20 fractions
48 received
 64 Gy in
 32 fractions
113 received







 stases at 
 baseline
274 included in meta-analysis
168 received radiotherapy plus
 carbogen and nicotinamide
BCON trial
333 patients randomly assigned (1:1)
BC2001 trial
458 patients randomly assigned
(partial factorial 2 × 2; 1:1)*†
165 received radiotherapy
 alone









161 included in meta-analysis
182 received radiotherapy plus
 MMC and FU
      149 received standard
 radiotherapy plus 
 MMC and FU
      33 received reduced 
  high-dose volume
  radiotherapy plus
  MMC and FU
276 received radiotherapy alone
 198 received standard
  radiotherapy alone 
 78 received reduced
  high-dose volume
  radiotherapy alone
Figure 1: Trial profiles and final dataset
MMC=mytomicin C. FU=fluorouracil. *98 excluded from chemotherapy randomisation (radiotherapy plus chemotherapy vs radiotherapy alone): 53 ineligible for chemotherapy; 34 withdrew or were 
withdrawn by physician; four had other reasons; and seven had unknown reasons. †239 excluded from radiotherapy randomisation (standard radiotherapy vs reduced high-dose volume radiotherapy): 
84 entered the trial after radiotherapy randomisation closed; 54 at centres not participating in radiotherapy randomisation; 47 with multiple tumours; 44 withdrew or were withdrawn by physician; 
and ten with administrative or unknown reasons.
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available values for variables in the model. Heterogeneity 
between trials was assessed by considering an interaction 
effect between fractionation schedule and trial.
In subgroup analyses, we explored the fractionation 
effect within trials and in patients who received radio-
therapy alone for invasive locoregional control, overall 
survival, and toxicity to assess robustness of results; 
aHR was the output with adjustment for the same factors 
as in the primary analyses. To investigate the effect of 
fractionation schedule on HRQOL in the BC2001 trial 
only, we employed similar methods as used for the trial’s 
HRQOL substudy, with mean change from baseline in 
FACT-BL (including TOTAL and subscale) scores sum-
marised at each timepoint.18 Only patients with paired 
baseline and follow-up data were included in the analysis. 
A 1% significance level and corresponding 99% CIs were 
considered to account for multiple timepoints and 
subscales of interest.18 Our post-hoc analysis of bladder-
cancer specific survival is outlined in the appendix (p 9).
Forest plots of fractionation effects on each outcome 
were used to graphically assess the degree of overlap 
between the 95% CIs of each trial. Data were analysed with 
Stata (version 15.0) and the R (version 3.6.0) survival19 and 
geepack20 packages. Analysis was based on a data snapshot 
on July 11, 2016, for BC2001 and Oct 1, 2018, for BCON.
Expanded details of our statistical methods are provided 
in the appendix (pp 3–4).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Of 458 patients in the BC2001 trial, 456 were included in 
the meta-analysis (fractionation schedule was unknown 
for two patients); 279 (61%) received 32 fractions and 
177 (39%) received 20 fractions. Median follow-up was 
118 months (IQR 100–137). Of 333 patients in the BCON 
trial, 326 were included in the meta-analysis 
BC2001 trial BCON trial Combined dataset
64 Gy in 
32 fractions 
(n=279)





64 Gy in 
32 fractions 
(n=97)





64 Gy in 
32 fractions 
(n=376)






Female 50 (18%) 37 (21%) ·· 17 (18%) 48 (21%) ·· 67 (18%) 85 (21%) ··
Male 229 (82%) 140 (79%) 7·5% 80 (82%) 181 (79%) 8·7% 309 (82%) 321 (79%) 7·9%
Age, years 71·4 (8·7) 71·6 (7·9) 1·3% 72·6 (7·6) 73·0 (7·8) –5·4% 71·7 (8·4) 72·4 (7·8) 7·9%
Radiotherapy plus radiosensitiser 111 (40%) 71 (40%) 0·7% 49 (51%) 116 (51%) 0·3% 160 (43%) 187 (46%) 7·1%
Reduced high-dose volume radiotherapy 75 (27%) 35 (20%) 16·9% 0 0 ·· 75 (20%) 35 (9%) 32·8%
Tumour stage
1 1* (<1%) 0 ·· 13 (13%) 17 (7%) ·· 14 (4%) 17 (4%) ··
2 251 (90%) 129 (73%) ·· 68 (70%) 147 (64%) ·· 319 (85%) 276 (68%) ··
3 20 (7%) 40 (23%) ·· 14 (14%) 54 (24%) ·· 34 (9%) 94 (23%) ··
4 7 (3%) 8 (5%) 47·6% 2 (2%) 10 (4%) 32·1% 9 (2%) 18 (4%) 42·6%
Unknown 0 0 ·· 0 1 ·· 0 1 ··
Tumour grade
1 1 (<1%) 0 ·· 0 0 ·· 1 (<1%) 0 ··
2 40 (14%) 19 (11%) ·· 16 (16%) 30 (13%) ·· 56 (15%) 49 (12%) ··
3 236 (85%) 156 (89%) 13·9% 81 (84%) 198 (87%) 9·4% 317 (85%) 354 (88%) 11·1%
Unknown 2 2 ·· 0 1 ·· 2 3 ··
Extent of resection
Biopsy or not resected 24 (9%) 23 (13%) ·· 25 (26%) 62 (28%) ·· 49 (13%) 85 (22%) ··
Complete 175 (63%) 81 (47%) ·· 46 (47%) 83 (38%) ·· 221 (59%) 164 (42%) ··
Partial 77 (28%) 70 (40%) 34·4% 26 (27%) 73 (33%) 19·6% 103 (28%) 143 (36%) 36·1%
Unknown 3 3 ·· 0 11 ·· 3 14 ··
Neoadjuvant chemotherapy 65 (23%) 69 (39%) 34·4% 0 0 ·· 65 (17%) 69 (17%) 0·8%
Haemoglobin, g/dL† 13·1 (1·8) 12·6 (1·8) 27·4% 13·8 (1·7) 13·6 (1·6) 11·3% 13·2 (1·8) 13·1 (1·8) 5·7%
Data are n (%), mean (SD), or n. Standardised difference represents the difference in means or proportions divided by its standard error; it is therefore a measure of the average difference between groups 
expressed in standard deviation units. A difference greater than 10% expresses that the observed difference between fractionation groups is more than 10% of the observed variability. Percentages were 
calculated for total number of patients without missing values. *This tumour was deemed to be pathological stage T1, but radiological staging confirmed the tumour as T3 and the patient was considered to be 
eligible for the trial. †Unknown in four patients receiving 64 Gy in 32 fractions (one in BC2001 and three in BCON) and two patients receiving 55 Gy in 20 fractions (BCON).
Table 1: Baseline characteristics
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(fractionation schedule was unknown for five patients 
and two further patients were found to have metastases 
at baseline); 97 (30%) received 32 fractions and 229 (70%) 
received 20 fractions. Median follow-up was 159 months 
(IQR 91–181). Our combined dataset therefore consisted 
of 782 patients of whom 376 (48%) received 32 fractions 
and 406 (52%) received 20 fractions (figure 1). Median 
follow-up in the combined dataset was 120 months 
(IQR 99–159).
Patient characteristics in the combined dataset showed 
imbalances between fractionation groups (table 1) with 
respect to tumour stage, tumour grade, and extent of 
resection. The imbalance in the proportion receiving 
reduced high-dose volume radiotherapy in BC2001 
reflects the partial two-by-two design and the fact that the 
radiotherapy randomisation closed first.5
218 (28%) of 782 patients had invasive locoregional 
recurrence within 5 years: 106 (28%) of 376 receiving 
32 fractions and 112 (28%) of 406 receiving 20 fractions. 
Median follow-up in our analysis of invasive locoregional 
control was 60 months (IQR 21–60). Invasive locoregional 
control rates over time per trial and fractionation group 
are summarised in figure 2A. In the combined dataset, 
crude one-stage meta-analysis gave an HR of 0·83 
(95% CI 0·63–1·10) for patients receiving 20 fractions 
versus those receiving 32 fractions (appendix p 5). After 
accounting for age, sex, trial intervention, extent of 
resection, tumour stage, haemoglobin, and use of 
neoadjuvant chemotherapy, the 20 fraction schedule had 
a lower hazard than the 32 fraction schedule (aHR 0·71 
[95% CI 0·52–0·96]; figure 3A; appendix pp 5–6). As the 
upper limit of the 95% CI for both the crude and adjusted 
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Invasive locoregional control at 3 years (95% CI)
 BC2001 64 Gy in 32 fractions: 74·2% (67·9−79·4)
 BC2001 55 Gy in 20 fractions: 77·5% (69·5−83·6)
 BCON 64 Gy in 32 fractions: 56·2% (45·2−65·8)
 BCON 55 Gy in 20 fractions: 63·5% (56·3−69·9)
Overall survival at 5 years (95% CI)
 BC2001 64 Gy in 32 fractions: 42·8% (36·6−48·9)
 BC2001 55 Gy in 20 fractions: 41·3% (34·1−48·5)
 BCON 64 Gy in 32 fractions: 39·2% (29·8−48·5)
 BCON 55 Gy in 20 fractions: 45·2% (38·8−51·5)
Figure 2: Kaplan-Meier estimates of observed invasive locoregional control (A) and observed overall survival (B) by trial and fractionation group
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estimates was lower than the prespecified HRnon-inferiority 
(1·25), non-inferiority of the 20 fractions schedule could 
be concluded. The estimated fractionation effect within 
subgroups of treatment intervention is shown in the 
appendix (p 5). No significant heterogeneity across trials 
was found (χ²=0·066, p=0·80).
571 (73%) of 782 patients died during follow-up, 
273 (73%) of 376 who received 32 fractions and 298 (73%) 
of 406 who received 20 fractions. Overall survival rates 
over time per trial and fractionation group are shown in 
figure 2B. Crude one-stage meta-analysis of overall 
survival gave an HR of 0·99 (95% CI 0·83–1·18) for 
patients who received 20 fractions versus those who 
received 32 fractions (appendix p 7). After accounting for 
age, sex, trial intervention, extent of resection, tumour 
stage, and haemoglobin, the aHR was 0·87 (95% CI 
0·72–1·06; figure 3A; appendix pp 7–8). The estimated 
fractionation effect within subgroups of treatment inter-
vention for overall survival is shown in the appendix (p 7). 
The likelihood ratio test indicated some heterogeneity in 
fractionation effect across trials (χ²=5·37, p=0·02), as 
shown by fractionation effect being larger in the BCON 
trial (figure 3A). The post-hoc analysis of bladder cancer-
specific survival is shown in the appendix (p 9).
Bladder and rectum LENT-SOMA toxicity data in the 
BC2001 trial were available for analysis in 203 (73%) of 
279 patients receiving 32 fractions and 120 (68%) of 
177 receiving 20 fractions. In the BCON trial, data were 
available in 75 (77%) of 97 patients receiving 32 fractions 
and 175 (76%) of 229 receiving 20 fractions (table 2). In 
the combined dataset, 278 (74%) of 376 patients receiving 
32 fractions and 295 (73%) of 406 receiving 20 fractions 
had toxicity data available. The appendix (p 10) shows the 
distribution of baseline variables over fractionation 
groups in patients with data available for toxicity 
analysis. The proportion of patients with grade 3–4 
rectum or bladder toxicity within 5 years of radiotherapy 
treatment was similar between fractionation groups 
(table 2). The combined one-stage crude meta-analysis 
showed an RD of –2·88% (95% CI –11·15 to 5·39; 
appendix p 11) for 20 fractions versus 32 fractions. 
Similar results were obtained after adjusting age, sex, 
and trial intervention (adjusted RD [aRD] –3·37% 
[95% CI –11·85 to 5·10]; figure 3B; appendix pp 11–12). A 
similar difference in risk was found in a sensitivity 
analysis in which toxicities that occurred within 3 
months of a recurrence event were not censored 
(aRD –3·82% [95% CI –11·88 to 4·24]). As the upper 
limit of both the crude and adjusted 95% CI in our main 
analyses was smaller than RDnon-inferiority=10%, non-
inferiority of 20 fractions compared with 32 fractions in 
relation to 5-year bladder and rectum toxicity could be 
concluded. The estimated fractionation effect within 
subgroups of treatment intervention for late toxicity is 
shown in the appendix (p 11). The test for interaction 
between trial intervention and fractionation group was 
significant (p=0·0086).
In BC2001, baseline FACT-BL scores, as a measure 
of HRQOL, were balanced between fractionation 
schedules (appendix p 13). Although we observed a 
detrimental effect of 20 fractions versus 32 fractions at 
the end of treatment on the total score (estimated 
adjusted mean difference from baseline between 
fractionation groups –9·34 [99% CI –18·36 to –0·32], 
p=0·0077), this difference was not significant at 1 year 
(–1·29 [–12·31 to 9·72], p=0·76), nor at later times 
(appendix p 14).
The adjusted models of the combined dataset for 
invasive locoregional control, overall survival, and late 
toxicity (appendix pp 5, 7, 11) also provided estimates for 
the radiosensitiser effect. Significantly improved HRs 
were seen with a radiosensitiser compared with 
radiotherapy alone for invasive locoregional control 
(aHR 0·65 [95% CI 0·49–0·87]) and overall survival 
(aHR 0·83 [0·70–0·98]); and we observed no significant 
increase in late grade 3–4 rectum or bladder toxicity 
(aRD –1·40 [95% CI –9·43 to 6·63]).
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Figure 3: Forest plots of the fractionation effect of 64 Gy in 32 fractions versus 55 Gy in 20 fractions for 
invasive locoregional control and overall survival (A) and toxicity (B)
Invasive locoregional control combined HR estimates adjusted for age, sex, randomised treatment, extent of 
resection, tumour stage, haemoglobin, and neoadjuvant chemotherapy. Overall survival combined HR estimates 
adjusted for age, sex, randomised treatment, extent of resection, tumour stage, and haemoglobin. Invasive 
locoregional control and overall survival were modelled on random effects for treatment site and stratified by trial. 
Late rectum or bladder toxicity combined absolute RD estimates adjusted for age, sex, randomised treatment, and 
trial, with a random-effects model for treatment site. Models were adjusted on the subset of patients with 
available values for variables in the model. Red dotted line represents the non-inferiority margin. HR=hazard ratio. 
RD=risk difference.
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Discussion
To our knowledge, this study is the first to compare the 
outcomes of conventional fractionation with moderately 
hypofractionated radiotherapy for locally advanced bladder 
cancer. We found that hypofractionated radiotherapy with 
55 Gy in 20 fractions was non-inferior to 64 Gy in 
32 fractions in relation to invasive locoregional control and 
late bladder and rectum toxicity. Furthermore, since the 
95% CI for the aHR estimate excluded a value of 1 (no 
effect), the adjusted analysis suggested that the 20 fraction 
schedule improved invasive locoregional control at the 5% 
level, despite patients treated with 55 Gy in 20 fractions 
having poor prognostic factors. Non-inferiority was also 
confirmed across intervention subgroups, regardless of 
whether a patient was treated with radio therapy alone or 
radio therapy with radiosensitisation. Moreover, if the same 
HRnon-inferiority (1·25) was considered for overall survival, the 
adjusted model would also suggest non-inferiority of the 
20 fraction schedule. As such, there is a cogent argument 
for 55 Gy in 20 fractions being adopted as the standard of 
care in this patient group. Many studies from outside the 
UK advocate trimodality treatment with a complete 
transurethral resection of bladder being essential to 
undertake bladder preservation.21–23 Both the BC2001 and 
BCON trials had a high rate of local control despite high 
proportions of patients with incomplete resections. 
Although undertaking a complete transurethral resection 
of bladder might be optimal, the results of both trials 
suggest that bladder preservation can be achieved even in 
its absence.
Bladder cancer is considered a rapidly proliferating 
cancer, with a high α/β ratio of 10 Gy (and thus low 
fractionation sensitivity),24 and evidence suggests a loss 
of effective radiotherapy dose (γ radiation) of 0·2–0·4 Gy 
per day after approximately 5 weeks of treatment due to 
tumour cell repopulation (appendix p 15).25 In the linear-
quadratic model to predict radiobiological response, use 
of an α/β ratio of 10 Gy without accounting for overall 
treatment time suggests that 64 Gy in 32 fractions and 
55 Gy in 20 fractions have biologically effective doses 
(BEDs) of 76·8 Gy and 70·1 Gy. This difference is 
reduced when a time factor is included, with a maximum 
reduction for kick-off time (Tk; defined as the delay in 
tumour cell repopulation in response to radiotherapy) of 
28 days or less. If BED was calculated with γ=0·36 
and Tk=28 days, 64 Gy in 32 fractions and 55 Gy in 
20 fractions have BEDs of 71·0 Gy and 70·1 Gy 
respectively. For both schedules to be equivalent without 
a time factor, an α/β ratio of 2 for bladder cancer would 
be required. Based on our fractionation effect estimates, 
tumour repopulation appears substantial with the longer 
32-fraction regimen. Investigators have previously 
reported repopulation after 5 weeks.25,26 Results on the 
effect of the 32-fraction regimen in this study suggest 
that repopulation occurs from as early as 4 weeks. 
Further data on outcomes from different radiotherapy 
schedules would be required to optimise a predictive 
model based on dose, fractionation schedule, and 
survival outcome. However, the finding that a moderately 
hypofractionated radiotherapy schedule is non-inferior 
for locally advanced bladder cancer is mostly probably 
due to a combination of an α/β ratio lower than 10 and a 
substantial effect of repopulation. The overall treatment 
time for rapidly proliferating cancers at high risk of 
repopulation is crucial, with evidence of detrimental 
outcomes when treatment is interrupted and prolonged. 
Guidelines are available for accommodating unexpected 
gaps in treatment.27
Enhanced acute toxicity is a concern with a shortened 
radiotherapy schedule,28 but, in the present study, 
differences in data collection between the trials limited 
our assessment of acute toxicity. HRQOL data from the 
BC2001 trial did suggest worse quality of life at the end of 
treatment with the hypofractionated schedule, but this 
did not result in excess treatment interruptions;18 and 
after 6 months no difference in HRQOL between 
radiotherapy schedules was seen.
Although concern is often expressed about the risk of 
late toxicity with hypofractionated radiotherapy, our meta-
analysis showed no significant difference in late toxicity 
between fractionation regimens. Despite this finding, care 
should be taken when extrapolating these data to 
radiosensitisation with other treatments, such as 
immunotherapy, for which hypofractionation might have 
greater effect.29 Furthermore, no difference was observed 
in patient-reported HRQOL in the long-term after recovery 
from acute toxicity in the BC2001 trial. Published 5-year 
patient-reported outcomes showed excellent preservation 
of daily function with both fractionation schedules 
throughout the follow-up period.18 Our subgroup analysis 
of toxicity indicating a detrimental effect of 55 Gy in 
20 fractions in patients receiving a concurrent radio-
sensitiser should be interpreted with caution, as any 
differences might relate to a combined benefit from the 
64 Gy in 32 fractions 
(n=278)
55 Gy in 20 fractions 
(n=295)
2-year late toxicity
Rectum 7 (3%) 17 (6%)
Bladder 66 (24%) 74 (25%)
Rectum or bladder 69 (25%)* 82 (28%)†
5-year late toxicity
Rectum 8 (3%) 21 (7%)
Bladder 86 (31%) 88 (30%)
Rectum or bladder 89 (32%)‡ 97 (33%)§
LENT-SOMA urinary and rectal dysfunction subscales were recorded up to 5 years 
after radiotherapy in the BC2001 and BCON trials. LENT-SOMA=Late Effects 
Normal Tissue Task Force-Subjective, Objective, Management, Analytic. *Four 
patients with both. †Nine patients with both. ‡Five patients with both. 
§12 patients with both.
Table 2: LENT-SOMA grade 3–4 bladder or rectum toxicity after the end 
of treatment by fractionation groups
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sensitiser and hypofractionation prolonging recurrence-
free time, resulting in these patients having increased 
follow-up to collect toxicity data.
Innate challenges arise when combining data from 
two phase 3 trials with no preplanned meta-analysis. 
Acknowledging the limitations in this study, the primary 
outcome here differs from the primary endpoints in 
BC2001 (locoregional control, including non-muscle 
invasive bladder recurrences) and BCON (local relapse-
free survival, including invasive recurrences and death). 
Given that the BCON dataset contains information on 
recurrence of muscle-invasive lesions only, the BC2001 
trial secondary endpoint of invasive locoregional control 
was chosen as the primary endpoint for this meta-analysis 
as it could be defined in both trials. Furthermore, data 
collection differed between the trials, with toxicity data 
collected more frequently in the BCON trial than in the 
BC2001 trial. We overcame this issue by using cumulative 
reporting of adverse events over a common reporting 
period. BC2001 included prospective annual long-term 
follow-up beyond 5 years to collect basic information on 
the events of interest, while in BCON a one-off 
retrospective data collection was done to update follow-up 
data. To overcome this difference, we analysed invasive 
locoregional control within 5 years of follow-up only. 
Finally, comparison between trials was not randomised 
but driven by institutional practice differences, as 
reflected in the differing proportional split in fractionation 
regimens between the trials: 177 (39%) of 456 patients in 
the BC2001 trial received hypofractionated radiotherapy 
compared with 229 (70%) of 326 in the BCON trial. 
Although case-mix differences were included in the 
modelling, there might be unanticipated effects, such as 
confounding due to differences in clinical decision 
making. A randomised, controlled trial comparing both 
schedules would ideally provide the definitive evidence 
on the question of optimal radiotherapy schedule, but is 
unlikely to be feasible given the logistics, numbers of 
patients, and length of follow-up required. In the absence 
of such evidence, a meta-analysis of individual patient 
data from the two largest randomised, controlled trials on 
bladder preservation seems the best approach.
Shorter treatment protocols have numerous socio-
economic advantages in any health-care system. If 
evidence of superiority of treatment can be provided, 
with no difference in long-term side-effects or detriment 
to the patient experience, the protocol should be adopted 
as standard of care. Therefore, we recommend 55 Gy in 
20 fractions as a standard of care for bladder preservation 
in patients with locally advanced bladder cancer.
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